Research · Sep 3, 2026
[NTRA] Natera Thesis 2026: Signatera ctDNA MRD Drives Oncology Liquid Biopsy Adoption
Natera Inc. (NASDAQ: NTRA) FY2025 revenue ~$2.0-2.2B (+25-37%) with diluted EPS ~$0.30-0.55 reflecting continued post-2024 Signatera (personalized circulating tumor DNA molecular residual disease test) ~$0.7-0.9B aggregate revenue (+50-65% YoY) plus selected post-2024 Panorama (non-invasive prenatal testing NIPT) ~$0.55-0.65B revenue + Horizon (carrier screening) ~$0.20-0.25B + Empower (hereditary cancer screening) ~$0.10-0.15B + selected various Renasight (kidney) + Prospera (organ transplant) under continued co-founder + CEO Steve Chapman (~10-year tenure since 2015 sole CEO). Leading molecular + genetic testing diagnostics company with operations across US (selected major Austin Texas + San Carlos California labs) + selected various international. Founded 2003 in Redwood City California by Matthew Rabinowitz + Jonathan Sheena (~22-year heritage); selected post-2003 founding focused on molecular + genetic testing; selected post-2015 NASDAQ IPO (~$180M raised); selected post-2024 Signatera Medicare LCD coverage expansion across selected major indications. Headquartered in Austin Texas; ~3,500+ employees globally with ~$2.0-2.2B revenue. Five primary product franchises: Signatera (~35-40% revenue ~$0.7-0.9B), Panorama (~25-30% ~$0.55-0.65B), Horizon (~10% ~$0.20-0.25B), Empower (~5-7% ~$0.10-0.15B), Renasight + Prospera + selected various (~15-20% ~$0.30-0.40B). Signatera ctDNA MRD adoption cycle: ~$0.7-0.9B aggregate revenue FY2025 (+50-65% YoY); selected first-in-class personalized ctDNA MRD test using selected proprietary tumor-informed approach; selected ~50-70% aggregate US ctDNA MRD market share leadership; selected post-2024 Medicare LCD coverage expansion (colorectal + breast + lung + bladder + selected various); ~$3-5B+ aggregate peak sales potential. Panorama NIPT franchise leadership: ~$0.55-0.65B aggregate revenue FY2025 (+10-15% YoY); ~50%+ aggregate US NIPT market share leadership; selected post-2024 Panorama AI + selected continued post-2024 international expansion. Selected various test menu: Horizon (carrier screening) ~$0.20-0.25B + Empower (hereditary cancer) ~$0.10-0.15B + Renasight (kidney) ~$0.05-0.10B + Prospera (organ transplant rejection monitoring) ~$0.10-0.15B. Co-founder + CEO Steve Chapman since 2015 sole CEO (~10-year tenure); CFO Mike Brophy; CMO Solomon Moshkevich. Capital structure: ~$0.85-1.0B aggregate cash + investments; no dividend; no buybacks (capital priority on growth + Signatera commercial launch); selected continued FCF positive trajectory inflection FY2024-2025 (~5-10% FCF margin FY2025); investment-grade B2/B credit rating. FY2026 thesis: Signatera ctDNA MRD adoption cycle + Panorama NIPT continued growth + selected various test menu expansion + FCF expansion + selected potential FY2027 commercial inflection. Risks: reimbursement compression, Guardant Health + Foundation Medicine + Roche + Quest Diagnostics competitive intensity, NIPT + carrier screening + hereditary cancer cyclical, ~$0.4-0.5B annual R&D execution, USD/EUR + selected various international currency volatility.